PRASUGREL COMPARED WITH HIGH LOADING-AND MAINTENANCE-DOSE CLOPIDOGREL IN PATIENTS WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION: THE PRASUGREL IN COMPARISON TO CLOPIDOGREL FOR INHIBITION OF PLATELET ACTIVATION AND AGGREGATION-THROMBOLYSIS IN MYOCARDIAL INFARCTION 44 TRIAL, by Wiviott et al.
For patients with acute coronary syndromes, and particularly for those undergoing percutaneous intervention (PCI), the use of clopidogrel has evolved toward higher loading doses and potentially higher maintenance dosing. This practice is driven by the desire to achieve greater levels of platelet inhibition and to overcome the specter of resistance. Recent data from the very large randomized controlled TRITON-TIMI 38 study demonstrated that prasugrel, a potent thienopyridine, reduced rates of ischemic events but resulted in a small increase in risk of major bleeding in patients with acute coronary syndromes and PCI compared with standard dose clopidogrel. In this issue of Circulation, Wiviott and colleagues compare inhibition of platelet aggregation with prasugrel to that of high dose clopidogrel in patients undergoing PCI in the PRINCIPLE-TIMI 44 study. At 2 important time points (6 hours after loading and 14 days into maintenance), the use of prasugrel was associated with a greater degree of inhibition of platelet aggregation than was clopidogrel, a finding that emerged very early and was seen at all time points. These data suggest that this agent can allow more potent platelet inhibition than even aggressive current strategies, and they provide an underlying mechanism for the clinical findings in the TRITON study. See p 2923. 
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